Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | HTR3A | P46098 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4361686 | 0.88 | SLC6A1 (0.41) | TDP1GABRA5LMNATSHRGABRA1 | |
| SCHEMBL4904229 | 0.88 | SLC6A1 (0.41) | TDP1GABRA5LMNATSHRGABRA1 | |
| SCHEMBL4908632 | 0.88 | SLC6A1 (0.41) | TDP1GABRA5LMNATSHRGABRA1 | |
| SCHEMBL1062380 | 0.84 | — | — | |
| SCHEMBL14414058 | 0.84 | USP2 (0.42) | LMNATSHRALOX15KDM4EUSP2 | |
| SCHEMBL7705221 | 0.84 | USP2 (0.42) | LMNATSHRALOX15KDM4EUSP2 | |
| SCHEMBL22660169 | 0.82 | TDP1 (0.39) | TDP1GABRA5LMNATSHRGABRA1 | |
| SCHEMBL121125 | 0.80 | LMNA (0.39) | LMNATSHRALOX15KDM4EUSP2 | |
| SCHEMBL1710717 | 0.80 | LMNA (0.39) | LMNATSHRALOX15KDM4EUSP2 | |
| SCHEMBL20879049 | 0.80 | LMNA (0.41) | TDP1GABRA5LMNATSHRGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2024-09-19 | — | — | US | disclosed |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2024-07-09 | — | — | US | disclosed |
| EP-3558981-B1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| EP-3138842-B1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | ZHEJIANG DTRM BIOPHARMA CO LTD (CN) | 2020-12-09 | — | — | EP | disclosed |
| CN-108295073-B | Polyfluoro compounds as bruton's tyrosine kinase inhibitors | 浙江导明医药科技有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-10300066-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| CN-108431000-A | New compound as dnmt rna inhibitor | 基础应用医学研究基金会 | 2018-08-21 | — | — | CN | disclosed |
| US-20180207161-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2018-07-26 | — | — | US | disclosed |
| CN-108295073-A | Multi-fluorinated compounds are as bruton's tyrosine kinase inhibitor | 浙江导明医药科技有限公司 | 2018-07-20 | — | — | CN | disclosed |
| EP-3092227-B1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-07-11 | — | — | EP | disclosed |
| US-9346807-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| WO-2015165279-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | 浙江导明医药科技有限公司 | 2015-11-05 | — | — | WO | disclosed |
| CN-105017256-A | Polyfluorinated compound Bruton tyrosine kinase inhibitor | ZHEJIANG DAOMING PHARMACEUTICAL CO LTD | 2015-11-04 | — | — | CN | disclosed |
| WO-2015080446-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-04 | — | — | WO | disclosed |
| EP-2857404-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2012024179-A1 | SUBSTITUTED AMIDE DERIVATIVES AS DGAT-1 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011135376-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| CN-1143848-C | 2-arylethyl- (piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists | - | 2004-03-31 | — | — | CN | disclosed |
| CN-1295563-A | 2-arylethyl- (piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2001-05-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | TDP1 1688/4885GABRA5 1707/4885LMNA 2970/4885 |
| US-20180207161-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | BTK, LCK, LYN | TDP1 459/4885GABRA5 1216/4885LMNA 4457/4885 |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | TDP1 1138/4885GABRA5 2763/4885LMNA 2856/4885 |
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | TDP1 1392/4885GABRA5 2663/4885LMNA 2622/4885 |
| US-10300066-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | BTK, LCK, LYN | TDP1 459/4885GABRA5 1216/4885LMNA 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.